Pharmaceutical R&D on neuropathic pain

This is an area to share and learn about new Medical Advances and Techniques where we can be educated and educate.
Dave
Posts: 142
Joined: Fri Sep 23, 2011 3:43 pm

Re: Pharmaceutical R&D on neuropathic pain

Post by Dave »

jogom wrote:By the way, i found that very interesating page
http://www.nature.com/nrd/journal/v11/n ... nrd3624_T1.
Thanks. A good find at that link is Ralfinamide, a drug in phase 2.  The maker is Newron Pharmaceuticals, an Italian company. They claim that Ralfinamide is an inhibitor of sodium channels, calcium channels, and NMDA receptors.
jogom
Posts: 22
Joined: Fri Apr 06, 2012 6:08 pm

Re: Pharmaceutical R&D on neuropathic pain

Post by jogom »

and finally
http://www.biocetera.com/inthenews.php?id=148537
I hope it can be on the market soon.
jogom
Posts: 22
Joined: Fri Apr 06, 2012 6:08 pm

Re: Pharmaceutical R&D on neuropathic pain

Post by jogom »

Does anybody hear aboute XEN402?
Dave
Posts: 142
Joined: Fri Sep 23, 2011 3:43 pm

Re: Pharmaceutical R&D on neuropathic pain

Post by Dave »

jogom wrote:Does anybody hear aboute XEN402?
This drug is interesting because Xenon looks for cures by studying the "opposite phenotype."   For example, they have been looking for chronic pain cures by studying the genes of people who congenitally cannot feel pain.  It is one of the few  companies really looking at pain from a DNA level.

This drug XEN402 is targeted to a very specific sodium channel in the nerve associated with pain.  Let's HOPE it is successful... 
jogom
Posts: 22
Joined: Fri Apr 06, 2012 6:08 pm

Re: Pharmaceutical R&D on neuropathic pain

Post by jogom »

I gess you mean the SCN9A of a pakistani family. I see you know a lot of companies that are involved on research.
Dave
Posts: 142
Joined: Fri Sep 23, 2011 3:43 pm

Re: Pharmaceutical R&D on neuropathic pain

Post by Dave »

Nektar Therapeutics (CA) is another company doing some interesting work. Their main focus seems to be using their polymer drug delivery technology to reduce the adverse effects of opioids:

scroll down to the "pain" section:
http://www.nektar.com/product_pipeline/ ... l#NKTR-171

http://www.marketwatch.com/story/nektar ... 2012-06-07
Dave
Posts: 142
Joined: Fri Sep 23, 2011 3:43 pm

Re: Pharmaceutical R&D on neuropathic pain

Post by Dave »

See also news on Sativex (GW Pharma). This product is a marijuana extract in a spray form. The first application is cancer pain, but it will also be trialed for neuropathic pain.

http://americannewsreport.com/marijuana ... 14518.html

http://www.gwpharm.com/sativex.aspx

http://www.gwpharm.com/Third%20phase%20 ... ences.aspx
Dave
Posts: 142
Joined: Fri Sep 23, 2011 3:43 pm

Re: Pharmaceutical R&D on neuropathic pain

Post by Dave »

This is a very long way from being commercially available, but if there is any to this gene therapy for neuropathic pain, it would be a phenomenal breakthrough. If our great grandchildren can simply go to the doctor and be cured of this....

http://www.diamyd.com/docs/ntddsPlatfor ... on=science
Dave
Posts: 142
Joined: Fri Sep 23, 2011 3:43 pm

Re: Pharmaceutical R&D on neuropathic pain

Post by Dave »

Btw, here is another company in Virginia and another in Spain.

http://www.xdynia.com
http://www.esteve.es/EsteveFront/Cargar ... idi&lng=en
User avatar
helenlegs 11
Posts: 1779
Joined: Fri Sep 17, 2010 9:39 am
Location: North East England

Re: Pharmaceutical R&D on neuropathic pain

Post by helenlegs 11 »

deadly-black-mamba-venom-could-kill-pain

http://news.sky.com/story/992914/deadly ... -kill-pain
Fall 2008. Misdiagnosed with lumber spine problem. MRN June 2010 indicated pudendal entrapment at Alcocks canal. Diagnosed with complex variant piriformis syndrome with sciatic, pudendal and gluteal entrapment's by Dr Filler 2010.Guided piriformis botox injection 2011 Bristol. 2013, Nerve conduction test positive; new spinal MRI scan negative, so diagnosed for the 4th time with pelvic nerve entrapment, now recognised as Sciatic, pudendal, PFCN and cluneal nerves at piriformis level.
Post Reply

Return to “MEDICAL ADVANCES & EDUCATION”